Avayl
Entrepreneur First '23Berlin, DE · Founded 2023 · 2 known investors
Avayl builds MedPro, an end-to-end AI platform for Medical Information and Medical Affairs teams in pharma and biotech, offering 100+ pre-built AI capabilities that integrate into existing systems. The product is designed for compliance, scientific rigor, and auditable outputs to support content generation for medical information professionals.
Also known as AVAYL · AVAYL GmbH
Founders & leadership
Avayl was founded in 2023 by Miena Amiri and Alexander Götz.
Investors · 2
Company profile
researched Aug 2026Avayl (AVAYL GmbH) is a Berlin-headquartered technology company founded in 2023 that develops AI-native workflow software for Medical Affairs and Medical Information functions in pharmaceutical and biotech organizations. Its flagship product, MedPro, is described by the company as an end-to-end, pre-built AI platform for medical content that offers more than 100 AI capabilities and connects into a customer's existing systems and workflows in under 24 hours. The company frames the product around three properties: processing speed, scientific rigor, and compliance, with outputs documented and auditable by design.
MedPro is used for medical inquiry handling, systematic literature analysis and screening, summarization of scientific studies, question answering over large literature sets, and generation of scientific and medical content that internal experts review and approve. Third-party descriptions characterize MedPro as a cloud-based SaaS platform that centralizes data and automates routine tasks, and state that it works with verified scientific data sets combined with the customer's own data while keeping human experts in control of the workflow.
Alongside the software, Avayl runs an "AI Academy" — a free webinar and resource series on applying AI in Medical Information, including sessions on AI explainability and auditability — developed with industry associations MILE (Medical Information Leaders Europe), phactMI and PIPA, whose representatives sit on an advisory board together with Avayl's two founders.
Founding story
Avayl was founded in 2023 in Berlin by Dr. Miena Amiri and Alexander Götz. Amiri is a medical doctor and former Merck manager with a PhD in Medical Psychology; Götz is a former optimization physicist in the semiconductor industry and former CERN researcher. Secondary reporting states the pair set out to address inefficiencies in how medical affairs teams handle inquiries and data in the pharmaceutical industry, processes described as labor-intensive and prone to delays.
Business model
Software vendor selling the MedPro platform to pharmaceutical and biotechnology companies; a secondary source describes it as a cloud-based software-as-a-service platform deployed into customers' existing systems, and the company markets a four-month pilot as an entry path.
Not specified in the sources beyond a SaaS platform characterization for MedPro.
Traction
The website cites pilot outcomes of up to 75% productivity gain in response creation for a global Medical Information team and quality on par with or better than MI professionals working alone, and a 40–75% productivity range at scale; a customer testimonial comes from a Global Medical Information Manager at Recordati. A secondary source states MedPro has managed over 1 million medical inquiries and cites up to 80% productivity gains. LTS reported significant time savings and reduced manual research and analysis. Avayl describes itself as VC-backed and lists Entrepreneur First, Another VC and a seed investor among its backers.
Latest developments
An AI Academy live webinar on AI explainability and auditability in Medical Affairs is scheduled for 17 July 2026, and the company lists five open Berlin roles (Commercial Growth Manager, Senior Legal Counsel – Enterprise & Partnerships, Executive Operations Assistant, Strategic Projects Manager, Full-Stack Developer).
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positions itself as the only end-to-end, purpose-built AI platform for Medical Information; secondary coverage describes it as a technology company driving AI-native workflow systems in Medical Affairs with a focus on regulatory standards in the European market.
Claimed differentiators are a pre-built, end-to-end system rather than general writing assistance, deployment into existing systems in under 24 hours, 100+ domain-specific AI capabilities, compliance-by-design with documented and auditable outputs, and a founding team combining clinical/pharma and deep-tech physics backgrounds.
Technology
AI applied to regulated medical content workflows: more than 100 pre-built AI capabilities, integration into existing customer systems in under 24 hours, and auditable, documented outputs. Secondary descriptions cite natural language processing for categorizing and prioritizing inquiries, intelligent triage and routing, AI-assisted drafting with evidence-based references drawn from integrated databases, and automated literature search and summarization, all with human review before release. The platform is stated to operate on verified scientific data sets combined with company-owned data.
Go-to-market
Direct enterprise sales via demo requests and pilots, supported by content marketing (AI Cheat Sheet, implementation reference guide) and the AI Academy webinar series run with industry associations MILE, phactMI and PIPA. Partner introductions have also played a role: the LTS collaboration originated through networking by the 5-HT Chemistry & Health digital hub and was showcased at the 5-HT Innovators Club.
Medical Information and Medical Affairs teams at pharmaceutical, biotech and life sciences organizations, including global medical information teams and R&D, marketing and market intelligence functions; named users include LTS Lohmann Therapie-Systeme and Recordati Rare Diseases.
Geography
Headquartered at Monbijouplatz 5, 10178 Berlin, Germany, with all listed open roles in Berlin; customers and association partners are primarily European (Germany, Europe-wide associations), with secondary sources describing global life science customers.
History
Founded in 2023, the company began a collaboration with LTS Lohmann Therapie-Systeme AG in fall 2023, which was presented at the 5-HT Innovators Club in Heidelberg in September 2024 and published as a case study in October 2024. Encyclopedic secondary coverage also references work with Recordati Rare Diseases, the MILE association and Unbiased Science. The company later launched the AI Academy webinar series with industry associations and, as of the latest site snapshot, was hiring across commercial, legal, operations, product and engineering roles in Berlin.
Risks & controversies
Most performance claims (productivity gains, inquiry volumes, quality parity) originate from the company's own website or secondary summaries rather than independently verified data, and the two sources differ (75–80% productivity, 40–75% at scale). A directory entry for AVAYL on EU-Startups lists a materially different business description (portfolio optimization for pharma) and a 'Above €25 million' total funding figure that is not corroborated by any other source and may be inaccurate or refer to a different entity.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsLive 60-minute session with Q&A in Avayl's AI Academy series, developed with industry associations MILE, phactMI and PIPA.
Dr. Patrick Mohr (Corporate Vice President R&D, LTS) and Dr. Miena Amiri (CEO, Avayl) presented the collaboration at the 5-HT Innovators Club in Heidelberg; a success story was published on 31 October 2024.
LTS Lohmann Therapie-Systeme AG began working with Avayl in fall 2023 after being introduced via the 5-HT network, using the MedPro platform to accelerate systematic literature analysis, scientific content creation and drug evaluation.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- AVAYL | AI for Medical Affairsavayl.tech · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Avayl do?
- Berlin-based company building MedPro, an AI platform for Medical Information and Medical Affairs teams in life sciences.
- Who founded Avayl?
- Avayl was founded by Miena Amiri, Alexander Götz in 2023.
- Who are Avayl's investors?
- Avayl's investors include Entrepreneur First, SquareOne.
- Where is Avayl headquartered?
- Avayl is headquartered in Berlin, DE.